In a report published Tuesday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Edwards Lifesciences Corp. EW, and raised the price target from $120.00 to $130.00.
In the report, Morgan Stanley noted, “Guidance for 2015 was consistent with Street models, but recent TAVR strength suggests upside is likely. Sapien 3 is not included in 2015 guidance and based on expedited MDT reviews will likely prove conservative. Our Bull case is $175 but requires loftier assumptions a few years out.”
Edwards Lifesciences Corp. closed on Monday at $132.13.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in